Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$2.47 - $6.77 $115,504 - $316,585
-46,763 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$5.22 - $11.86 $244,102 - $554,609
46,763 New
46,763 $305,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $119M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track 1623 Capital LLC Portfolio

Follow 1623 Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 1623 Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on 1623 Capital LLC with notifications on news.